ImpediMed enters into Harvard agreement

Company News

ImpediMed Limited (ASX:IPD) has entered into an agreement with the Harvard Clinical Research Institute located in Boston, Massachusetts to advance research around BIS in fluid detection.
 
Initial activities under the agreement include organising and managing a medical advisory board to assess the use of BIS in chronic heart failure patients.
 
ImpediMed specialises in providing technology to measure, monitor and manage fluid status and body composition. 
 
The company says it believes its BIS technology could provide a cost effective solution for better management of fluid detection and accumulation in chronic disease management.
 
ImpediMed Limited reported a net loss of $14.8 million at 30 June 2015.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.